274 related articles for article (PubMed ID: 7688467)
21. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
[TBL] [Abstract][Full Text] [Related]
23. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity.
Soriano E; Marco-Contelles J; Tomassi C; Nguyen Van Nhien A; Postel D
J Chem Inf Model; 2006; 46(4):1666-77. PubMed ID: 16859298
[TBL] [Abstract][Full Text] [Related]
24. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
25. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
[TBL] [Abstract][Full Text] [Related]
26. 3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (TSAO) pyrimidine nucleosides.
Camarasa MJ; Pérez-Pérez MJ; San-Félix A; Balzarini J; De Clercq E
J Med Chem; 1992 Jul; 35(15):2721-7. PubMed ID: 1495006
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2'- and 5'-positions of the sugar moiety.
Ingate S; Pérez-Pérez MJ; De Clercq E; Balzarini J; Camarasa MJ
Antiviral Res; 1995 Jun; 27(3):281-99. PubMed ID: 8540750
[TBL] [Abstract][Full Text] [Related]
28. [2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1.
Balzarini J; Pérez-Pérez MJ; San-Félix A; Velazquez S; Camarasa MJ; De Clercq E
Antimicrob Agents Chemother; 1992 May; 36(5):1073-80. PubMed ID: 1510396
[TBL] [Abstract][Full Text] [Related]
29. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.
Velázquez S; Alvarez R; Pérez C; Gago F; De Clercq E; Balzarini J; Camarasa MJ
Antivir Chem Chemother; 1998 Nov; 9(6):481-9. PubMed ID: 9865386
[TBL] [Abstract][Full Text] [Related]
30. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3-N- methyl-thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dio xide).
Balzarini J; Naesens L; Bohman C; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E
Biochem Pharmacol; 1993 Jul; 46(1):69-77. PubMed ID: 8102234
[TBL] [Abstract][Full Text] [Related]
31. Exploring the role of the 5'-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives.
Chamorro C; Pérez-Pérez MJ; Rodríguez-Barrios F; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
Antiviral Res; 2001 Jun; 50(3):207-22. PubMed ID: 11397508
[TBL] [Abstract][Full Text] [Related]
32. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Vrang L; Walbers J; Zhang H; Oberg B; Vandamme AM; Camarasa MJ; De Clercq E
Virology; 1993 Jan; 192(1):246-53. PubMed ID: 7685964
[TBL] [Abstract][Full Text] [Related]
33. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
[TBL] [Abstract][Full Text] [Related]
34. TSAO-T analogues bearing amino acids at position N-3 of thymine: synthesis and anti-human immunodeficiency virus activity.
Chamorro C; De Clercq E; Balzarini J; Camarasa MJ; San-Félix A
Antivir Chem Chemother; 2000 Jan; 11(1):61-9. PubMed ID: 10693655
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
36. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Chamorro C; Camarasa MJ; Pérez-Pérez MJ; de Clercq E; Balzarini J; San Félix A
Antivir Chem Chemother; 1998 Sep; 9(5):413-22. PubMed ID: 9875394
[TBL] [Abstract][Full Text] [Related]
37. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
Boyer PL; Ding J; Arnold E; Hughes SH
Antimicrob Agents Chemother; 1994 Sep; 38(9):1909-14. PubMed ID: 7529011
[TBL] [Abstract][Full Text] [Related]
38. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
39. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
Balzarini J
Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
